Viking Therapeutics has strong R&D, dual-track obesity drugs, and solid cash runway. Click here to read an analysis of VKTX ...

ARKG has rebounded sharply with a high-risk, high-reward genomics focus, despite sector weakness and macro headwinds. Find ...

Eli Lilly's Alzheimer's drug, donanemab (Kisqali), just got a thumbs-up from the European Medicines Agency's (EMA) expert ...

Investing.com -- Goldman Sachs has initiated coverage on Gubra A/S with a “neutral” rating and a 12-month price target of Dkr520, representing a 23.9% upside from the current price of Dkr419.80, in a ...

In the first quarter, Kathleen S. Wright Associates Inc. slashed its stake in Johnson & Johnson by a hefty 21.1%, unloading 1 ...